News report 📈 Stocks 🌍 United States

Bridgewater and ARK Diverge on Nvidia and Eli Lilly Holdings in Q2

Bridgewater and ARK Invest show shared interest in Eli Lilly and Nvidia, yet adopt opposing trading patterns as Bridgewater reduces its Nvidia exposure while ARK aggressively expands its position.

📅 September 16, 2026 🕐 1 min read

2 assets impacted (Stocks). Net bias: 0 Bullish, 0 Bearish, 2 Neutral. Strongest signal: LLY → 3/10 (55% confidence).

📊 Affected Assets (2)

LLY

Neutral 🤖 55%

📅 Short-term 🌍 US · Explicit

Eli Lilly is held by both Bridgewater and ARK, with strong growth in obesity and diabetes drugs but high valuation concerns.

NVDA

Neutral 🤖 55%

📅 Short-term 🌍 US · Explicit

Nvidia is a common holding, with Bridgewater trimming and ARK adding, reflecting mixed views on the stock.

🎯 Key Takeaways

Bridgewater increased its Eli Lilly stake to 87,023 shares, while ARK added 64,578 shares during the second quarter.
Bridgewater reduced its Nvidia position by over 826,000 shares, contrasting with ARK's addition of 345,821 shares.
Eli Lilly trades at a 61% premium to the healthcare sector median, sparking debate over whether growth justifies the valuation.

📝 Executive Summary

Bridgewater Associates and ARK Invest reveal contrasting strategies in their latest 13F filings, with both firms maintaining significant positions in Eli Lilly and Nvidia. While Bridgewater trimmed its massive Nvidia stake, ARK increased its exposure, highlighting a split in sentiment regarding the chipmaker's valuation and growth trajectory.

❓ FAQ

Why are investors divided on Eli Lilly's current valuation?

While bulls point to 48% revenue growth driven by Mounjaro and Zepbound, bears argue the stock's high P/E ratio leaves it vulnerable if sales growth normalizes.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article